secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cogent Biosciences, Inc. (COGT)
CIK:        0001622229
Form:       8-K
Filed at:   2022-03-15T23:59:59+00:00
Accession:  0001564590-22-010231
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cogent Biosciences Q4/FY2021 net loss $24.9M/$72.3M; three bezuclastinib trials enrolling
--------------------------------------------------------------------------------

- Cash $219.7M at Dec 31, 2021, sufficient to fund operations into 2024.
- APEX Phase 2 trial in AdvSM on track for initial data in H1 2022; SUMMIT (NonAdvSM) and PEAK (GIST) actively enrolling.
- Raised ~$38M via ATM in Q4 2021; shares sold at $9.25-$10.30.
- R&D expenses $55.9M in FY2021 vs $25.7M in FY2020, driven by trial start-up costs and research team expansion.
- Appointed Dr. Zamaneh Mikhak as SVP Head of Clinical Development; R&D Investor Event on April 8, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1622229/000156459022010231/0001564590-22-010231-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1622229/000156459022010231/cogt-8k_20220315.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-010231

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer